Iron-focused red blood cell trial data and therapies eyed for catalysts
Bitopertin phase III data for red blood cell disorders is expected soon, with additional polycythemia vera data planned for SOHO. Expanded access and launch plans are underway.
Key clinical programs are targeting red blood cell disorders through heme and iron pathways, with pivotal phase III data on bitopertin expected soon and broad market potential for anemia therapies. Expanded access and launch plans are underway, while new data for polycythemia vera are set to be presented at SOHO.